Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 4Active not recruiting 3Recruiting 2Withdrawn 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Burkitt Lymphoma 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Extranodal NK-T-Cell 2Neoplasm, Residual 1Lymphohistiocytosis, Hemophagocytic 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1Down Syndrome 1

Interventions

Cyclophosphamide 11venetoclax 10Dexamethasone 8Cytarabine 7Vincristine 5Azacitidine 4mogamulizumab 3fludarabine phosphate 3fludarabine 3daratumumab 3Specimen Handling 3Prednisone 3Methotrexate 3Doxorubicin 3Dasatinib 3Biopsy 3ruxolitinib 2prednylidene 2pegaspargase 2nelarabine 2deltacortene 2calaspargase pegol 2Rituximab 2Mercaptopurine 2Etoposide 2Decitabine 2Daunorubicin 2Calcium Dobesilate 2Bortezomib 2Asparaginase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × pegaspargase × Clear all
NCT00501826 2026-01-07

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

M.D. Anderson Cancer Center

Phase 2 Recruiting
160 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06376721 2024-04-19

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

Beijing Tongren Hospital

Phase 1/2 Recruiting
43 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡